Skip Navigation

Research Projects

Read about some of our current research projects:

Project 1: Gene-hormone interaction and risk of breast cancer

The overall hypothesis of this study is that common genetic variants can be used to classify women into low or neutral risk groups for developing breast cancer due to HT use (gene-hormone interaction). We will identify genetic variants using data and samples from the Hormone Therapy Trial (HT) of the Women's Health Initiative (WHI) study. Results from this study could benefit millions of women who suffer from menopausal symptoms. The identified genetic variants will be used to create a risk-benefit profile for HT treatment and may potentially improve clinical decision making for HT use. Individual HT-breast cancer risk assessment is important for identifying women for whom the benefits may outweigh the risks versus those women in whom the risks outweigh the benefits.

Project 2: The Role of CHD1 in DNA Rearrangements and Progression of PCa

The overall hypothesis of this study is that loss of the chromatin remodeler CHD1 leads to genomic DNA rearrangement which results in DNA copy number alterations (CNAs) at other critical genes, thereby driving cancer progression. The primary goals in aim 1 are: 1) to confirm the associations between deletion of CHD1 and CNAs identified in our pilot study, thereby to identify the CHD1 associated collaborative network in PCa; 2) to determine whether loss of CHD1 is associated with tumorigenesis at early stages and/or cancer progression at advanced stages. The goal of aim 2 is to evaluate the in vitro causal effects of knockdown CHD1 expression in response to oxidative stress on DAN damage, genesis of DNA rearrangement in terms of CNAs, differentially altered gene expression, and cellular or growth characteristics.  In aim 3 we will explore the in vivo causal effects of loss of CHD1 and MAP3K7 on tumorigenesis, pathological characteristics, invasion and metastases.  

Project 3: The Identification of Novel, Inherited Genetic Markers for Aggressive PCa in European and African Americans Using Whole Genome Sequencing

The overall hypothesis is that inherited sequence variants in the genome are associated with a lethal (aggressive) form of PCa but not indolent PCa, and the difference in these variants between races may contribute to higher incidence of mortality from aggressive PCa in AA.

Quick Reference

Genomics Center
Find A Doctor Ways to Give
Last Updated: 02-13-2016
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.